Our population will keep getting older, increasing healthcare costs, therefore calling for new solutions to treat age-related diseases.
Biotechnology is the solution for a healthier lifespan and reduced healthcare spending.
By investing and thus enabling transformative healthcare companies in their scientific breakthroughs, we will impact human health within the next 10 years.
We leverage potential by combining traditional funding with venture building, accomplishing a bigger and more diverse value creation in Europe and the US.
In our Venture Lab, we partner with scientific experts and turn untapped technologies into transformational companies. This way we acquire founder shares at nominal value– offering unique upsides to our investors.
Scientific & operational expertise
Building top teams
Access to capital & strong syndicates
Risk minimization by conducting killer experiments
Investing in best-in-class companies
Alongside of our venture lab approach, we generate additional value by identifying best-in-class companies at an early stage. Based on breakthrough science and led by amazing founders, we help those companies accelerate.
ACCESS
Access through extensive network and trust due to our deep knowledge
Successful track record since 2017
Accelerate
Leading players in follow on investment rounds
Support by talent and leadership recruitment, guidance on R&D as well as clinical trial and indication selection strategies.
ENABLING BREAKTHROUGHS
Through our extensive network we are able to partner with leading universities, research institutes and top investors in the US and Europe.
Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both Dravet Syndrome and ALS
